A detailed history of Bank Of America Corp transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Bank Of America Corp holds 284,939 shares of IMCR stock, worth $9.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
284,939
Previous 175,668 62.2%
Holding current value
$9.26 Million
Previous $5.95 Million 49.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.06 - $41.49 $3.28 Million - $4.53 Million
109,271 Added 62.2%
284,939 $8.87 Million
Q2 2024

Aug 14, 2024

SELL
$33.78 - $63.75 $955,332 - $1.8 Million
-28,281 Reduced 13.87%
175,668 $5.95 Million
Q1 2024

May 15, 2024

BUY
$60.14 - $75.36 $2.82 Million - $3.53 Million
46,867 Added 29.84%
203,949 $13.3 Million
Q4 2023

Feb 14, 2024

BUY
$42.85 - $69.5 $2.56 Million - $4.15 Million
59,663 Added 61.24%
157,082 $10.7 Million
Q2 2023

Aug 14, 2023

BUY
$48.54 - $61.64 $4.7 Million - $5.97 Million
96,836 Added 16609.95%
97,419 $5.84 Million
Q1 2023

May 12, 2023

BUY
$46.12 - $65.71 $92 - $131
2 Added 0.34%
583 $28,000
Q4 2022

Feb 10, 2023

SELL
$45.51 - $65.08 $26,941 - $38,527
-592 Reduced 50.47%
581 $33,000
Q3 2022

Nov 14, 2022

SELL
$37.34 - $57.44 $61,237 - $94,201
-1,640 Reduced 58.3%
1,173 $55,000
Q2 2022

Aug 12, 2022

SELL
$25.46 - $37.72 $102,323 - $151,596
-4,019 Reduced 58.83%
2,813 $104,000
Q1 2022

May 16, 2022

BUY
$18.94 - $34.29 $62,009 - $112,265
3,274 Added 92.02%
6,832 $204,000
Q4 2021

Feb 08, 2022

BUY
$27.58 - $40.0 $35,991 - $52,200
1,305 Added 57.92%
3,558 $121,000
Q3 2021

Nov 15, 2021

BUY
$27.98 - $40.0 $58,981 - $84,320
2,108 Added 1453.79%
2,253 $84,000
Q2 2021

Sep 13, 2021

BUY
$32.22 - $41.5 $4,671 - $6,017
145 New
145 $6,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.43B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.